HC Wainwright Issues Positive Forecast for RARE Earnings

Key Points

• HC Wainwright raised its Q3 2025 earnings estimate for Ultragenyx Pharmaceutical to ($1.15) per share from ($1.25), maintaining a "Buy" rating with a target price of $80.00.
• Ultragenyx recently reported a quarterly earnings result of ($1.17) EPS, surpassing estimates, and observed a revenue increase of 13.2% year-over-year, totaling $166.50 million.
• Despite positive adjustments from HC Wainwright, other brokers have reduced their price targets, indicating a more cautious outlook for the stock amid various market influences.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, August 6th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($1.15) for the quarter, up from their prior estimate of ($1.25). HC Wainwright currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($4.85) EPS, Q1 2026 earnings at ($1.74) EPS, Q2 2026 earnings at ($1.51) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($0.99) EPS and FY2026 earnings at ($5.57) EPS.

A number of other brokerages have also commented on RARE. Guggenheim reiterated a "buy" rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Wells Fargo & Company lowered their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, July 10th. Wedbush lowered their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Morgan Stanley lowered their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, July 14th. Finally, Canaccord Genuity Group decreased their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Stock Down 1.0%

RARE stock traded down $0.29 during midday trading on Friday, reaching $27.54. The stock had a trading volume of 1,527,932 shares, compared to its average volume of 2,814,751. The business has a fifty day simple moving average of $33.32 and a two-hundred day simple moving average of $36.73. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -4.98 and a beta of 0.25. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The company had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same period last year, the company posted ($1.52) earnings per share. The firm's quarterly revenue was up 13.2% compared to the same quarter last year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the business. California State Teachers Retirement System lifted its stake in Ultragenyx Pharmaceutical by 0.3% in the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock valued at $3,284,000 after acquiring an additional 268 shares in the last quarter. GAMMA Investing LLC lifted its stake in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 323 shares in the last quarter. Xponance Inc. lifted its stake in Ultragenyx Pharmaceutical by 2.8% in the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after acquiring an additional 347 shares in the last quarter. BOKF NA lifted its stake in Ultragenyx Pharmaceutical by 5.0% in the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock valued at $336,000 after acquiring an additional 382 shares in the last quarter. Finally, Oak Ridge Investments LLC increased its position in shares of Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after purchasing an additional 395 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.